Operational Efficiency Evaluation Of Bio-pharmaceutical Industry

In China, the bio-pharmaceutical industry stay in an excellent developmentenvironment. First,the policy support on the development of bio-pharmaceuticalindustry. The industry is easily affected by the policy. Second，raising the level ofhealth is good for stable development of the bio-pharmaceutical industry. With therapid development of China’s national economy and the level of health care continuesto improve, more and more people are able to consume relatively high price ofbio-pharmaceuticals. However, there are many problems of bio-pharmaceuticalindustry，for example insufficient proportion of R&D investment, weak researchand innovation capability, low technological achievements conversion rate and excesscapacity over competition issues. In this context, evaluating the bio-pharmaceuticalindustry operating performance is benefit to promote the stability of the industry andto improve its competitiveness.In this paper, a method based on BCC model and Malmquist Productivity IndexModel to evaluate China bio-pharmaceutical industry operating performance.Selecting the25main listed bio-pharmaceutical companies as samples. Based onindustry standards SFC division, there are12companies belonging to biologicalproducts industry,12companies belong to the bio-pharmaceutical industry, only onebelonging to other biological products industry. In this paper, taking the total assets,the main business costs and fees as input indicators, taking the main business incomeand net profit as output indicators.Using BCC model，this paper analyzes operational efficiency25main listedbio-pharmaceutical companies s in the year of2008-2012. And a combination withMalmquist productivity index model analyzes dynamic evaluation operationalefficiency25main listed bio-pharmaceutical companies s in the year of2008-2012.The results show: First, the efficiency of static evaluation results significantly lowerdue to the size, and the sample period of the bio-pharmaceutical industry, mainlyoperating performance of listed companies is relatively low, the need to improve.Second, the use of dynamic evaluation results showed decreased levels of technicalchange is total factor efficiency decline.Finally, I made a summary of research findings, and conclusions based onempirical research, put forward corresponding countermeasures and suggestions in order to promote the stable development of the bio-pharmaceutical industry.